A1C Almanac

Main Page

When Stress Hormones Rewrite the Gut

Posted

by

dr Karunia Valeriani Japar

Table of Contents
Category:
Tags: , , , ,

Keywords: Gut-Cortisol Axis, Gut-Brain-Metabolic Axis, Intestinal Barrier Integrity, 11b-Hydroxysteroid Dehydrogenase (11b-HSD1), Metabolic Aging

Introduction

The hypothalamic–pituitary–adrenal (HPA) axis integrates psychological and physical stress into a coordinated endocrine response, with cortisol as its principal effector hormone. Chronic HPA overactivity is increasingly recognized as a central mechanism linking stress, inflammation, and metabolic dysfunction, particularly in relation to obesity, insulin resistance, and mood disorders such as depression. In this context, cortisol acts not only as a systemic metabolic regulator but also as a key intermediary between the central nervous system and peripheral organs.

Beyond its classical systemic effects, cortisol interfaces intimately with the gut–brain axis, exerting direct actions on intestinal epithelial cells, mucosal immune populations, and the resident microbiome. Through these pathways, glucocorticoids influence intestinal barrier integrity, modulate luminal immune surveillance, and shape microbial community structure and function. This positions cortisol as a pivotal modulator of gut homeostasis, capable of shifting the intestinal environment toward either resilience or vulnerability under conditions of chronic stress.

Emerging experimental and clinical data demonstrate that stress-induced elevations of glucocorticoids can increase intestinal permeability via several converging mechanisms. These include alterations in tight junction protein expression and localization, activation of mucosal mast cells, and induction of pro-inflammatory cytokine cascades. The resultant disruption of barrier function facilitates translocation of microbial products and dietary antigens into the systemic circulation, promoting a state of low-grade, chronic inflammation.

This inflammation, in turn, further activates the HPA axis and exacerbates cortisol dysregulation, establishing a pathogenic feed-forward loop. Within this framework, the “gut–cortisol axis” can be conceptualized as a self-reinforcing circuit in which cortisol both damages and is secondarily driven by the intestinal barrier. Over time, this bidirectional interplay between stress hormones and gut integrity may accelerate trajectories toward metabolic disease, cardiometabolic complications, and age-related physiological decline, positioning the gut–cortisol axis as a promising target for preventive and therapeutic strategies in aging and longevity medicine.

Physiology of the HPA Axis and Cortisol

In response to internal or external stressors, the hypothalamic–pituitary–adrenal (HPA) axis is activated through the release of corticotropin-releasing factor (CRF) from paraventricular neurons of the hypothalamus, which stimulates adrenocorticotropic hormone (ACTH) secretion from the anterior pituitary. ACTH then acts on the zona fasciculata of the adrenal cortex to promote steroidogenesis and increase circulating cortisol concentrations, a process that unfolds over minutes and supports adaptation to real or anticipated energetic demands. Under physiological conditions, this axis operates within a tightly regulated negative-feedback loop in which cortisol binds to mineralocorticoid and glucocorticoid receptors in the hypothalamus, pituitary, and limbic structures to restrain further CRF and ACTH release. Superimposed on this feedback architecture is a robust circadian pattern, with cortisol levels peaking in the early morning and declining toward a nadir at night, a rhythm that coordinates metabolic readiness with the sleep–wake cycle [1,2,3,4,5].

Cortisol exerts pleiotropic metabolic effects that collectively mobilize energy substrates and enhance short-term survival. In the liver, it promotes gluconeogenesis and increases hepatic glucose output; in skeletal muscle and other protein-rich tissues, it stimulates proteolysis to provide amino acid precursors for glucose production; and in adipose tissue, it augments lipolysis, increasing circulating free fatty acids and glycerol. These actions are accompanied by modulation of cardiovascular tone and immune function, enabling an organism to meet acute energetic and inflammatory challenges. However, when glucocorticoid exposure is prolonged, chronic activation of glucocorticoid receptors leads to receptor downregulation and functional “glucocorticoid resistance,” which blunts feedback sensitivity and sustains cortisol elevation. This state has been linked to hippocampal atrophy, impaired synaptic plasticity, and memory deficits, as well as a shift toward a pro-inflammatory milieu that collectively underpins a chronic stress phenotype with adverse metabolic and neuropsychiatric consequences [1,3,4,5,6,7,8,9,10].

Architecture of the Intestinal Barrier

The intestinal barrier is a multi-layered defense system that physically and immunologically separates the host from the external environment of the gut lumen. It consists of a mucus layer rich in antimicrobial peptides, an epithelial monolayer joined by intercellular junctional complexes, underlying immune cells within the lamina propria, and an intricate vascular and neural network that coordinates local and systemic responses. Within the epithelial layer, tight junctions form the most apical component of the junctional complex and are critical determinants of paracellular permeability and epithelial polarity. These tight junctions are composed of transmembrane proteins such as occludin, members of the claudin family, and junctional adhesion molecules (JAMs), which are linked to the actin cytoskeleton via cytosolic scaffold proteins including zonula occludens (ZO)-1, ZO-2, and ZO-3 [11,12,13,14,15,16].

Figure 1. Structure of the physical barrier and the chemical barrier in the small (A) and large (B) intestine [13]

Under physiological conditions, this barrier architecture allows highly selective uptake of nutrients, electrolytes, and water while preventing uncontrolled passage of microorganisms and luminal antigens, thereby limiting both mucosal and systemic inflammatory activation. Disruption of tight junction structure or signalling, whether via altered expression, phosphorylation, or mislocalization of key proteins results in increased paracellular flux (“leaky gut”) and has been implicated in the pathogenesis of inflammatory bowel disease, celiac disease, and disorders of gut–brain interaction such as irritable bowel syndrome. A broad range of modulators, including dietary nutrients, microbial metabolites, pro- and anti-inflammatory cytokines, and stress mediators such as corticotropin-releasing factor (CRF), dynamically regulate tight junction function by influencing protein composition and actomyosin cytoskeletal tension. Through these mechanisms, the intestinal barrier emerges as a highly plastic interface at which environmental, microbial, and host-derived signals converge to shape local and systemic immune and metabolic homeostasis [13,15,16,17,18,19].

Stress, CRF, and Cortisol Effects on Gut Permeability

Both acute and chronic stress have been consistently shown to increase intestinal permeability in animal models and human subjects, predominantly through corticotropin-releasing factor (CRF)–mediated mast cell activation and downstream inflammatory cascades. Peripheral administration of exogenous CRF recapitulates many of the gastrointestinal effects observed during stress, including augmented ion and water secretion, mucin release, and disassembly of tight junction complexes. These effects are attenuated by CRF receptor antagonists such as astressin and by mast cell stabilizers such as lodoxamide, and are absent in mast cell–deficient animal models, underscoring the critical role of the CRF–mast cell axis in stress-induced barrier dysfunction. Upon activation by CRF, mucosal mast cells degranulate and release proteases and tumor necrosis factor-α (TNF-α), both of which contribute significantly to epithelial barrier disruption. At the molecular level, TNF-α enhances paracellular permeability through upregulation and activation of myosin light chain kinase (MLCK), which phosphorylates myosin and triggers contraction of the perijunctional actomyosin ring, leading to redistribution, internalization, and downregulation of tight junction proteins including occludin and zonula occludens-1 (ZO-1) [16,18,20,21,22,23].

Figure 2. Mechanisms described for GC modulation of intestinal epithelial cells based on in vitro models. In basal conditions (left), GCs may enhance barrier function via MKP-1 dependent mechanisms and inhibit proliferation and wound healing. In the presence of inflammatory cytokines (TNF, right), MLCK2 is upregulated and increases permeability, a mechanism that is counteracted by GCs. Expression of TJ tightening proteins may be also enhanced. TNF levels may be reduced by the immunomodulatory actions of GCs acting on other cell types. IL-10 may potentiate GC actions by increasing expression of the GR. The mechanisms depicted are derived from different studies and thus are not necessarily consistent [21].

In human experimental models of psychosocial stress such as public speaking tasks and dichotomous listening challenges transient elevations in circulating cortisol have been correlated with measurable increases in paracellular permeability, particularly in individuals exhibiting high cortisol responses, and with altered expression of barrier-related genes. Although the magnitude of effect appears dependent on stressor intensity and individual variability, these findings demonstrate that acute psychological stress can increase intestinal permeability in humans via mechanisms involving CRF and mast cell activation. Over time, repeated or chronic stressors appear to shift the intestinal barrier into a persistently “primed” state characterized by low-grade inflammation, increased responsiveness to luminal triggers, and heightened susceptibility to symptom generation in disorders of gut–brain interaction. This establishes a mechanistic interface through which cortisol dysregulation can directly propagate systemic inflammatory and metabolic consequences via impaired gut barrier integrity, thereby contributing to the pathogenesis of metabolic disease and accelerated aging [16,17,24,25,26,27,28].

Figure 3. Stress-related changes in the gut affect the immune system, peripheral organs, and brain [26]

Extra-Adrenal Glucocorticoid Generation and 11b-HSD Enzymes

Glucocorticoid tone at the tissue level is not solely determined by circulating cortisol concentrations, but rather by local regeneration and inactivation of glucocorticoids mediated by 11β-hydroxysteroid dehydrogenase (11β-HSD) isoenzymes. The type 1 isoform, 11β-HSD1, functions predominantly as a reductase in intact cells and catalyses the conversion of inactive cortisone to active cortisol, thereby amplifying local glucocorticoid receptor activation and cellular glucocorticoid signalling within adipocytes, hepatocytes, and intestinal epithelial cells, even in the context of normal circulating cortisol levels. Conversely, 11β-HSD2 catalyses the reverse reaction, inactivating cortisol to cortisone and serves primarily to protect mineralocorticoid receptors from cortisol occupancy, particularly in the distal nephron and colon. In obesity and aging, 11β-HSD1 expression is selectively increased in visceral and subcutaneous adipose tissue, creating a state of localized glucocorticoid excess that phenocopies many features of metabolic syndrome including central adiposity, insulin resistance, and dyslipidemia despite normal or even suppressed systemic cortisol levels [29,30,31,32,33,34,35,36].

Experimental models have robustly demonstrated the causal role of adipose-specific 11β-HSD1 overexpression in metabolic pathology. Transgenic mice engineered to overexpress 11β-HSD1 selectively in adipose tissue develop visceral obesity, hepatic steatosis, insulin resistance, and elevated circulating triglycerides and free fatty acids, recapitulating the hallmarks of human metabolic syndrome. Conversely, global or tissue-specific knockout of 11β-HSD1 confers resistance to diet-induced obesity, improves hepatic and peripheral insulin sensitivity, and protects against gluconeogenesis and dyslipidemia, underscoring the enzyme’s pivotal role in energy partitioning and metabolic homeostasis. Beyond adipose tissue, extra-adrenal glucocorticoid synthesis also occurs within the intestinal epithelium, where 11β-HSD1 and steroidogenic enzymes are expressed at low basal levels but are strongly upregulated in response to immunological stress and inflammatory cytokines such as tumor necrosis factor-α. In the intestinal mucosa, local glucocorticoid generation appears to participate in mucosal immune regulation and anti-inflammatory responses; however, chronic upregulation or dysregulation of this system may compromise barrier integrity, promote dysbiosis, and amplify systemic inflammatory load, particularly when combined with systemic HPA axis activation. Conceptually, this suggests a “dual-hit” model in which circulating cortisol driven by central HPA activation and local 11β-HSD1–mediated cortisol amplification in adipose and intestinal compartments synergize to impair both metabolic signalling and barrier integrity, thereby propagating a feed-forward loop of inflammation and metabolic dysfunction [31,35,37,38,39,40,41,42].

Microbiome-HPA-Metabolic Interactions

The gut microbiota engages in bidirectional communication with the hypothalamic–pituitary–adrenal (HPA) axis through multiple pathways, including microbial metabolites, vagal afferent signalling, immune mediators, and neuroendocrine feedback loops, collectively described as the gut–brain–metabolic axis. This reciprocal signalling enables the microbiota to modulate central stress responses and, conversely, allows stress hormones to reshape microbial community structure and function. Dysbiosis, characterized by reduced microbial diversity, depletion of short-chain fatty acid (SCFA) producing taxa, and expansion of pathobionts compromises intestinal barrier integrity, increases paracellular permeability, and facilitates translocation of bacterial products such as lipopolysaccharide (LPS) into the systemic circulation, a state termed metabolic endotoxemia. This endotoxemia triggers systemic inflammation via activation of Toll-like receptor 4 (TLR4) on immune cells and adipocytes, inducing pro-inflammatory cytokines such as interleukin-6 (IL-6), tumor necrosis factor-α, and interleukin-1β, which in turn further activate the HPA axis and perpetuate cortisol elevation. Conversely, chronic cortisol excess directly alters microbial composition and mucosal secretory profiles, favouring pro-inflammatory and obesogenic phenotypes and reducing populations of beneficial butyrate-producing genera such as Faecalibacterium and Roseburia [43,44,45,46,47,48,49,50,51,52].

Recent reviews emphasize that perturbations in the gut–brain–metabolic axis are strongly associated with insulin resistance, visceral adiposity, and mood disorders, mediated by shared inflammatory pathways, oxidative stress, and alterations in neurotransmitter synthesis including serotonin, dopamine, and gamma-aminobutyric acid. In the context of metabolic disease, this creates a self-perpetuating loop in which psychological stress, gut symptoms, and metabolic abnormalities reinforce each other, complicating both diagnosis and therapeutic management. Interventions targeting the microbiota such as high-fiber dietary patterns, prebiotic supplementation (e.g., galacto-oligosaccharides), and select probiotic strains have demonstrated capacity to modulate HPA axis activity, reduce cortisol awakening responses, improve markers of insulin sensitivity, and attenuate depressive and anxiety-like behaviors in both preclinical and human studies. For example, prebiotic administration with galacto-oligosaccharides has been shown to reduce the cortisol awakening response and selectively modulate attention to emotional stimuli in healthy volunteers, while meta-analytic evidence from 46 randomized controlled trials indicates that probiotic supplementation significantly decreases circulating cortisol levels. Dietary fiber supplementation that selectively enriches SCFA-producing bacteria has been associated with improved glycemic control and lower hemoglobin A1c in individuals with type 2 diabetes, effects mediated through SCFA activation of G-protein coupled receptors and epigenetic regulation of metabolic and inflammatory genes. Collectively, these findings underscore the therapeutic relevance of the gut–cortisol axis as a modifiable target for preventing and managing metabolic disease and age-related decline through integrated microbiome-directed strategies [16,17,47,53,54,55,56,57,58,59,60].

Gut-Cortisol Axis in Metabolic Disease and Aging

Chronically elevated cortisol promotes central adiposity, hepatic gluconeogenesis, and skeletal muscle catabolism, thereby recapitulating the Cushingoid phenotype frequently observed in metabolic syndrome and related cardiometabolic conditions. Through 11β-HSD1–dependent local amplification, visceral adipose depots become sites of intracellular glucocorticoid excess, exacerbating insulin resistance via c-Jun N-terminal kinase (JNK) activation, promoting dyslipidemia through enhanced lipolysis and hepatic very-low-density lipoprotein (VLDL) secretion, and sustaining low-grade systemic inflammation characterized by elevated pro-inflammatory cytokines such as tumor necrosis factor-α and interleukin-6. In parallel, cortisol-induced disruption of intestinal barrier integrity and subsequent microbial product translocation further elevate systemic inflammatory load, accelerating endothelial dysfunction, compromising mitochondrial biogenesis and respiratory efficiency, and driving sarcopenic changes including impaired myofibrillar protein synthesis, increased proteolysis, and accumulation of damaged mitochondria that are hallmark features of biological aging. These processes converge to produce a vicious cycle wherein visceral adiposity, mitochondrial dysfunction, and chronic inflammation reciprocally reinforce cortisol dysregulation and barrier compromise, thereby propagating age-related metabolic decline [1,61,62,63,64,65,66,67].

Figure 4. Hypothetical progression of mitochondrial dysfunction during the development sarcopenia and possible windows for interventions [63]

Longitudinal and cross-sectional data indicate that HPA axis dysregulation and increased intestinal permeability are prevalent in disorders of gut–brain interaction, mood disorders such as depression, and metabolic diseases, all of which are associated with elevated cardiometabolic risk and reduced health span across the lifespan. As the gut–cortisol axis becomes progressively dysregulated whether through chronic psychosocial stress, circadian misalignment, dietary insufficiency, or microbial dysbiosis, the threshold for stress-induced metabolic decompensation lowers, rendering individuals increasingly vulnerable to modest dietary and lifestyle perturbations that would otherwise be well tolerated. This phenomenon reflects a state of “metabolic inflexibility” in which adaptive stress responses give way to maladaptive feed-forward loops characterized by impaired mitochondrial function, flattened cortisol rhythms, loss of microbial oscillations, and persistent inflammation. Conceptually, this positions gut barrier integrity, cortisol diurnal rhythm, and microbial diversity as integrated biomarkers and modulators of “metabolic age” or “biological resilience,” linking psychological stress, lifestyle exposures, and systemic aging processes into a unified framework with direct relevance for preventive medicine and longevity interventions [68,69,70,71,72,73,74,75].

Therapeutic and Lifestyle Modulation of the Gut-Cortisol Axis

Current evidence supports a multimodal therapeutic approach that simultaneously addresses HPA axis regulation, intestinal barrier support, and metabolic homeostasis. Behavioural and lifestyle interventions including sleep optimization, structured physical activity, and mind–body practices such as mindfulness meditation and yoga can normalize diurnal cortisol rhythms, reduce HPA axis reactivity, and improve gut–brain signalling. Sleep deprivation and circadian misalignment disrupt tight junction protein expression (occludin, claudin-1), impair mucin secretion, and exacerbate microbial dysbiosis, creating a bidirectional cycle wherein gut dysfunction perpetuates sleep fragmentation and vice versa. Regular moderate-intensity exercise, particularly when timed to align with circadian rhythms, enhances microbial diversity, promotes production of short-chain fatty acids (SCFAs) such as butyrate and propionate, and strengthens gut barrier function, collectively dampening systemic inflammation and HPA activation. From a dietary perspective, whole-food patterns emphasizing adequate protein intake, fermentable fibers, and polyphenol-rich plants such as those found in berries, green tea, and cruciferous vegetables support tight junction integrity,  restore microbial diversity, and reduce metabolic endotoxemia, thereby attenuating cortisol-driven metabolic dysregulation [19,28,76,77,78,79].

Figure 5. Intestinal barrier damage, flora disorder and microglia activation, destroy the blood-brain barrier, affect the function of neurotransmitters, and drive the HPA axis and multi-system linkage eventually leads to sleep disorders [76]

From a pharmacologic and nutraceutical standpoint, selective 11β-HSD1 inhibitors represent a promising therapeutic strategy to interrupt the gut–cortisol–metabolic loop by reducing local tissue-level amplification of glucocorticoid signalling. Preclinical studies and early clinical trials demonstrate that 11β-HSD1 inhibition improves insulin sensitivity, reduces fasting glucose, ameliorates dyslipidemia, and prevents atherosclerotic plaque progression in metabolic syndrome models, effects mediated through decreased hepatic gluconeogenesis and reduced visceral adipose glucocorticoid tone. Agents that directly enhance tight junction stability such as glutamine (5–10 g/day), zinc supplementation (zinc gluconate or zinc sulfate), and specific amino acids including tryptophan have been shown to upregulate zonula occludens-1 (ZO-1), occludin, and claudin expression, restore transepithelial electrical resistance, and protect against stress-induced and cytokine-mediated barrier disruption. Targeted probiotics, prebiotics, and postbiotic metabolites offer adjunctive therapeutic potential to restore barrier function and recalibrate the HPA axis; for example, prebiotic galacto-oligosaccharides have been shown to reduce waking cortisol responses in healthy volunteers, while meta-analytic evidence from 46 randomized controlled trials indicates that probiotic supplementation significantly lowers circulating cortisol levels and modulates stress-induced emotional processing. Postbiotics, including SCFAs and bacterial cell wall components, directly enhance tight junction assembly via histone deacetylase inhibition and activation of G-protein coupled receptors, offering a non-viable microbial therapeutic approach with reproducible potency and safety profiles [19,28,38,56,58,80,81,82,83,84,85,86,87].

Looking forward, future longevity-focused interventions will likely integrate stress biology assessment, intestinal barrier diagnostics such as zonulin and lipopolysaccharide-binding protein measurements and comprehensive microbiome profiling to personalize therapeutic strategies for preventing metabolic disease through targeted modulation of the gut–cortisol axis. Emerging precision medicine frameworks that incorporate multi-omic data (metagenomics, metabolomics, and host genomics) alongside clinical phenotyping enable identification of individual microbiome–metabolome signatures that predict responsiveness to specific dietary, probiotic, or pharmacologic interventions, thereby maximizing therapeutic efficacy and minimizing trial-and-error approaches. Such integrative strategies hold promise for not only reversing metabolic dysfunction but also extending health span by addressing the mechanistic convergence of stress, barrier integrity, and microbial ecology in age-related decline [69,76,88,89,90,91].

Conclusion

The gut–cortisol axis represents a critical convergence point at which psychological stress, endocrine signalling, intestinal barrier integrity, and microbiome composition jointly shape metabolic health and aging trajectories. When chronically activated, the HPA axis and local glucocorticoid-amplifying mechanisms converge on the gut to disrupt tight junction architecture, increase intestinal permeability, and drive compositional shifts in the microbiota that favour pro-inflammatory and obesogenic profiles. Even in the absence of overt hypercortisolism, this constellation of changes can sustain low-grade systemic inflammation, promote visceral adiposity, and accelerate cardiometabolic and neurocognitive decline, reframing metabolic disease and age-related conditions as disorders of stress biology and barrier resilience rather than of caloric excess and genetics alone.

From a clinical and translational perspective, this framework highlights the importance of routinely integrating assessment of stress patterns, gut-related symptoms, and surrogate markers of barrier and HPA function into preventive and therapeutic strategies. Such an approach may uncover modifiable leverage points, ranging from stress reduction and circadian alignment to targeted nutritional, microbiome-directed, and endocrine interventions that can interrupt self-reinforcing loops within the gut–cortisol axis. Moving forward, longitudinal, systems-level research is needed to delineate causal pathways, establish and validate robust biomarkers, and rigorously test multimodal interventions that simultaneously target stress regulation, intestinal permeability, and microbial ecology. By explicitly addressing the gut–cortisol interface, future longevity-focused and metabolic medicine paradigms may more effectively slow biological aging and reduce the burden of chronic metabolic disease.

Reference

  1. Thau L, Gandhi J, Sharma S. Physiology, Cortisol [Internet]. National Library of Medicine. StatPearls Publishing; 2023. Available from: https://www.ncbi.nlm.nih.gov/books/NBK538239/
  2. Lengton R, Myrte Schoenmakers, Brenda, Boon MR, Elisabeth. Glucocorticoids and HPA axis regulation in the stress–obesity connection: A comprehensive overview of biological, physiological and behavioural dimensions. Clinical Obesity. 2024 Dec 2;
  3. Cortisol Testing – Laboratory Diagnostics [Internet]. Ganzimmun.de. 2024. Available from: https://www.ganzimmun.de/en/laboratory/endocrinology/cortisol
  4. Sheng JA, Bales NJ, Myers SA, Bautista AI, Roueinfar M, Hale TM, et al. The Hypothalamic-Pituitary-Adrenal Axis: Development, Programming Actions of Hormones, and Maternal-Fetal Interactions. Frontiers in Behavioral Neuroscience [Internet]. 2021 Jan 13;14(601939). Available from: https://www.frontiersin.org/articles/10.3389/fnbeh.2020.601939/full
  5. Herman JP, McKlveen JM, Ghosal S, Kopp B, Wulsin A, Makinson R, et al. Regulation of the Hypothalamic-Pituitary-Adrenocortical Stress Response. Comprehensive Physiology [Internet]. 2016 Mar 15;6(2):603–21. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC4867107/
  6. Mcquade R. Physiology and pathology of HPA axis, anterior and posterior pituitary hormones [Internet]. Available from: https://madeinheene.hee.nhs.uk/Portals/19/R_ McQuade 30_10_19.pdf
  7. Bertollo AG, Santos CF, Bagatini MD, Ignácio ZM. Hypothalamus-pituitary-adrenal and gut-brain axes in biological interaction pathway of the depression. Frontiers in Neuroscience. 2025 Feb 6;19.
  8. Ring M. An Integrative Approach to HPA Axis Dysfunction: From Recognition to Recovery. The American Journal of Medicine. 2025 Jun;
  9. Conrad CD. Chronic Stress-induced Hippocampal Vulnerability: The Glucocorticoid Vulnerability Hypothesis. Reviews in the Neurosciences. 2008 Jan;19(6).
  10. Tatomir A. THE IMPACT OF STRESS AND GLUCOCORTICOIDS ON MEMORY. Clujul Medical. 2014 Mar 1;87(1):3–6.
  11. Kuo WT, Odenwald MA, Turner JR, Zuo L. Tight junction proteins occludin and ZO-1 as regulators of epithelial proliferation and survival. Annals of the New York Academy of Sciences [Internet]. 2022 Aug 1;1514(1):21–33. Available from: https://pubmed.ncbi.nlm.nih.gov/35580994/
  12. Oh-oka K, Kono H, Ishimaru K, Miyake K, Kubota T, Ogawa H, et al. Expressions of Tight Junction Proteins Occludin and Claudin-1 Are under the Circadian Control in the Mouse Large Intestine: Implications in Intestinal Permeability and Susceptibility to Colitis. Weber CR, editor. PLoS ONE. 2014 May 20;9(5):e98016.
  13. Neurath MF, Artis D, Becker C. The intestinal barrier: a pivotal role in health, inflammation, and cancer. The Lancet Gastroenterology & Hepatology [Internet]. 2025 Mar 11;10(6). Available from: https://www.sciencedirect.com/science/article/pii/S246812532400390X?utm_source=chatgpt.com#bib90
  14. Otani T, Nguyen TP, Tokuda S, Sugihara K, Sugawara T, Furuse K, et al. Claudins and JAM-A coordinately regulate tight junction formation and epithelial polarity. The Journal of Cell Biology [Internet]. 2019 Oct 7;218(10):3372–96. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6781433/
  15. Lee SH. Intestinal Permeability Regulation by Tight Junction: Implication on Inflammatory Bowel Diseases. Intestinal Research [Internet]. 2015;13(1):11. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4316216/
  16. Vanuytsel T, Bercik P, Boeckxstaens G. Understanding neuroimmune interactions in disorders of gut–brain interaction: from functional to immune-mediated disorders. Gut [Internet]. 2023 Apr 1;72(4):787–98. Available from: https://gut.bmj.com/content/72/4/787
  17. Grover M, Vanuytsel T, Chang L. Intestinal Permeability in Disorders of Gut-Brain Interaction: From Bench to Bedside. Gastroenterology [Internet]. 2024 Sep; Available from: https://www.sciencedirect.com/science/article/pii/S0016508524054167?via%3Dihub
  18. Rodiño-Janeiro BK, Alonso-Cotoner C, Pigrau M, Lobo B, Vicario M, Santos J. Role of Corticotropin-releasing Factor in Gastrointestinal Permeability. Journal of Neurogastroenterology and Motility. 2015 Jan 1;21(1):033–50.
  19. Suzuki T. Regulation of the intestinal barrier by nutrients: The role of tight junctions. Animal Science Journal. 2020 Jan;91(1).
  20. Overman EL, Rivier JE, Moeser AJ. CRF Induces Intestinal Epithelial Barrier Injury via the Release of Mast Cell Proteases and TNF-α. Karhausen J, editor. PLoS ONE. 2012 Jun 29;7(6):e39935.
  21. Tena-Garitaonaindia M, Arredondo-Amador M, Mascaraque C, Asensio M, Marin JJG, Martínez-Augustin O, et al. MODULATION OF INTESTINAL BARRIER FUNCTION BY GLUCOCORTICOIDS: LESSONS FROM PRECLINICAL MODELS. Pharmacological Research. 2022 Jan;106056.
  22. Kim DH, Cho YJ, Kim JH, Kim YB, Lee KJ. Stress-induced Alterations in Mast Cell Numbers and Proteinase-activated Receptor-2 Expression of the Colon: Role of Corticotrophin-releasing Factor. Journal of Korean Medical Science [Internet]. 2010 [cited 2019 Apr 30];25(9):1330. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2923781/
  23. Chatoo M, Li Y, Ma Z, Coote J, Du J, Chen X. Involvement of Corticotropin-Releasing Factor and Receptors in Immune Cells in Irritable Bowel Syndrome. Frontiers in Endocrinology. 2018 Feb 12;9.
  24. Nie HY, Ge J, Huang GX, Liu KG, Yue Y, Li H, et al. New insights into the intestinal barrier through “gut-organ” axes and a glimpse of the microgravity’s effects on intestinal barrier. Frontiers in Physiology. 2024 Oct 10;15.
  25. Abildinova GZ, Benberin VV, Vochshenkova TA, Afshar A, Mussin NM, Kaliyev AA, et al. The gut-brain-metabolic axis: exploring the role of microbiota in insulin resistance and cognitive function. Frontiers in Microbiology. 2024 Nov 26;15.
  26. Madison AA, Bailey MT. Stressed to the Core: Inflammation and Intestinal Permeability Link Stress-Related Gut Microbiota Shifts to Mental Health Outcomes. Biological Psychiatry [Internet]. 2023 Oct 29;95(4). Available from: https://www.sciencedirect.com/science/article/pii/S0006322323016591
  27. Gerdin L, González‐Castro AM, Ericson A, Mats Persborn, Santos J, Walter SA, et al. Acute psychological stress increases paracellular permeability and modulates immune activity in rectal mucosa of healthy volunteers. United European Gastroenterology Journal [Internet]. 2022 Oct 31 [cited 2024 Sep 3];11(1):31–41. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9892435/
  28. La Torre D, Van Oudenhove L, Vanuytsel T, Verbeke K. Psychosocial stress-induced intestinal permeability in healthy humans: What is the evidence? Neurobiology of Stress [Internet]. 2023 Nov 1;27:100579. Available from: https://www.sciencedirect.com/science/article/pii/S235228952300067X
  29. Morton NM, Seckl JR. 11&Bgr;-Hydroxysteroid Dehydrogenase Type 1 and Obesity. Obesity and Metabolism. 2008;146–64.
  30. Chapman K, Holmes M, Seckl J. 11β-Hydroxysteroid Dehydrogenases: Intracellular Gate-Keepers of Tissue Glucocorticoid Action. Physiological Reviews. 2013 Jul;93(3):1139–206.
  31. Ahmed A, Schmidt C, Brunner T. Extra-Adrenal Glucocorticoid Synthesis in the Intestinal Mucosa: Between Immune Homeostasis and Immune Escape. Frontiers in Immunology. 2019 Jun 25;10.
  32. Walker BR. Extra-adrenal regeneration of glucocorticoids by 11β-hydroxysteroid dehydrogenase type 1: physiological regulator and pharmacological target for energy partitioning. Proceedings of the Nutrition Society. 2007 Feb;66(1):1–8.
  33. Stimson RH, Andersson J, Andrew R, Redhead DN, Karpe F, Hayes PC, et al. Cortisol Release From Adipose Tissue by 11β-Hydroxysteroid Dehydrogenase Type 1 in Humans. Diabetes [Internet]. 2009 Jan 1;58(1):46–53. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2606892/
  34. Prasad SSV, Prashanth A, Kumar CP, Reddy SJ, Giridharan NV, Vajreswari A. A novel genetically-obese rat model with elevated 11beta-hydroxysteroid dehydrogenase type 1 activity in subcutaneous adipose tissue. Lipids in Health and Disease. 2010 Nov 17;9(1).
  35. Geer EB, Islam J, Buettner C. Mechanisms of Glucocorticoid-Induced Insulin Resistance. Endocrinology and Metabolism Clinics of North America [Internet]. 2014 Mar;43(1):75–102. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3942672/
  36. Tomlinson JW. 11Beta-hydroxysteroid dehydrogenase type 1 in human disease: a novel therapeutic target. Minerva endocrinologica [Internet]. 2005 Mar;30(1):37–46. Available from: https://pubmed.ncbi.nlm.nih.gov/15877012/
  37. Prasad SSV, Prashanth A, Kumar CP, Reddy SJ, Giridharan NV, Vajreswari A. A novel genetically-obese rat model with elevated 11beta-hydroxysteroid dehydrogenase type 1 activity in subcutaneous adipose tissue. Lipids in Health and Disease. 2010 Nov 17;9(1).
  38. Morgan SA, McCabe EL, Gathercole LL, Hassan-Smith ZK, Larner DP, Bujalska IJ, et al. 11β-HSD1 is the major regulator of the tissue-specific effects of circulating glucocorticoid excess. Proceedings of the National Academy of Sciences [Internet]. 2014 Jun 17;111(24):E2482–91. Available from: https://www.pnas.org/content/111/24/E2482
  39. Seckl JR. Glucocorticoids and 11beta-Hydroxysteroid Dehydrogenase in Adipose Tissue. Recent Progress in Hormone Research. 2004 Jan 1;59(1):359–93.
  40. Johnson JS, Opiyo MN, Thomson M, Gharbi K, Seckl JR, Heger A, et al. 11β-hydroxysteroid dehydrogenase-1 deficiency alters the gut microbiome response to Western diet. Journal of Endocrinology. 2017 Feb;232(2):273–83.
  41. Meduri GU. Synergistic glucocorticoids, vitamins, and microbiome strategies for gut protection in critical illness. Exploration of Endocrine and Metabolic Diseases [Internet]. 2025 May 14;2. Available from: https://www.explorationpub.com/Journals/eemd/Article/101432
  42. Li C, Xia J, Zhu W, Xin L, An C, Yang S, et al. Systemic overexpression of the 11β-HSD1 promotes endoplasmic reticulum stress in multiple tissues and the development of metabolic syndrome in mice. Molecular Medicine Reports. 2017 May;16(5):7738–44.
  43. Kasarello K, Cudnoch-Jedrzejewska A, Czarzasta K. Communication of gut microbiota and brain via immune and neuroendocrine signaling. Frontiers in Microbiology. 2023 Jan 25;14.
  44. Kopczyńska J, Kowalczyk M. The potential of short-chain fatty acid epigenetic regulation in chronic low-grade inflammation and obesity. Frontiers in immunology. 2024 Mar 27;15.
  45. Welcome To Zscaler Directory Authentication [Internet]. Nih.gov. 2026 [cited 2026 Feb 1]. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC12711672/
  46. Warren A, Nyavor Y, Beguelin A, Frame LA. Dangers of the chronic stress response in the context of the microbiota-gut-immune-brain axis and mental health: a narrative review. Frontiers in immunology. 2024 May 2;15.
  47. Halabitska I, Petakh P, Kamyshna I, Oksenych V, Kainov DE, Kamyshnyi O. The interplay of gut microbiota, obesity, and depression: insights and interventions. Cellular and Molecular Life Sciences. 2024 Oct 30;81(1).
  48. Moustakli E, Stavros S, Katopodis P, Potiris A, Drakakis P, Dafopoulos S, et al. Gut Microbiome Dysbiosis and Its Impact on Reproductive Health: Mechanisms and Clinical Applications. Metabolites [Internet]. 2025 Jun 11 [cited 2025 Aug 26];15(6):390. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC12195147/
  49. de Punder K, Pruimboom L. Stress Induces Endotoxemia and Low-Grade Inflammation by Increasing Barrier Permeability. Frontiers in Immunology. 2015 May 15;6.
  50. Han Y, Wang B, Gao H, He C, Hua R, Liang C, et al. Vagus nerve and underlying impact on the gut microbiota-brain axis in behavior and neurodegenerative diseases. Journal of Inflammation Research [Internet]. 2022 Nov;Volume 15:6213–30. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9656367/
  51. Rusch JA, Layden BT, Dugas LR. Signalling cognition: the gut microbiota and hypothalamic-pituitary-adrenal axis. Frontiers in Endocrinology [Internet]. 2023 Jun 19;14. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC10316519/
  52. Park JC, Chang L, Kwon HK, Im SH. Beyond the gut: decoding the gut–immune–brain axis in health and disease. Cellular and Molecular Immunology [Internet]. 2025 Aug 14; Available from: https://www.nature.com/articles/s41423-025-01333-3
  53. Oumaima Anachad, Amine Taouil, Taha WM, Bennis F, Chegdani F. The Implication of Short-Chain Fatty Acids in Obesity and Diabetes. Microbiology insights. 2023 Jan 1;16:117863612311627-117863612311627.
  54. Yu W, Sun S, Fu Q. The role of short-chain fatty acid in metabolic syndrome and its complications: focusing on immunity and inflammation. Frontiers in Immunology [Internet]. 2025 Feb 7;16. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC11842938/
  55. Huda MN, Kim M, Bennett BJ. Modulating the Microbiota as a Therapeutic Intervention for Type 2 Diabetes. Frontiers in Endocrinology. 2021 Apr 7;12.
  56. Jain M, Anand A, Sharma N, Shamim MA, Enioutina EY. Effect of Probiotics Supplementation on Cortisol Levels: A Systematic Review and Meta-Analysis. Nutrients. 2024 Oct 21;16(20):3564.
  57. Kopczyńska J, Kowalczyk M. The potential of short-chain fatty acid epigenetic regulation in chronic low-grade inflammation and obesity. Frontiers in immunology. 2024 Mar 27;15.
  58. Schmidt K, Cowen PJ, Harmer CJ, Tzortzis G, Errington S, Burnet PWJ. Prebiotic intake reduces the waking cortisol response and alters emotional bias in healthy volunteers. Psychopharmacology [Internet]. 2014 Dec 3;232(10):1793–801. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4410136/pdf/213_2014_Article_3810.pdf
  59. Abildinova GZ, Benberin VV, Vochshenkova TA, Afshar A, Mussin NM, Kaliyev AA, et al. The gut-brain-metabolic axis: exploring the role of microbiota in insulin resistance and cognitive function. Frontiers in Microbiology. 2024 Nov 26;15.
  60. Soto M, Herzog C, Pacheco JA, Fujisaka S, Bullock K, Clish CB, et al. Gut microbiota modulate neurobehavior through changes in brain insulin sensitivity and metabolism. Molecular Psychiatry [Internet]. 2018 Jun 18;23(12):2287–301. Available from: https://www.nature.com/articles/s41380-018-0086-5
  61. Damanti S, Senini E, De Lorenzo R, Merolla A, Santoro S, Festorazzi C, et al. Molecular constraints of sarcopenia in the ageing muscle. Frontiers in Aging. 2025 Jul 3;6.
  62. Liu CF, Tang WHW. Gut microbiota in sarcopenia and heart failure. The Journal of Cardiovascular Aging. 2022;2(3):35.
  63. Marzetti E, Calvani R, Cesari M, Buford TW, Lorenzi M, Behnke BJ, et al. Mitochondrial dysfunction and sarcopenia of aging: From signaling pathways to clinical trials. The International Journal of Biochemistry & Cell Biology. 2013 Oct;45(10):2288–301.
  64. Takeda Y, Masashi Demura, Mitsuhiro Kometani, Shigehiro Karashima, Aono D, Konishi S, et al. Epigenetic alterations of 11beta-hydroxysteroid dehydrogenase 1 gene in the adipose tissue of patients with primary aldosteronism. Endocrine Journal [Internet]. 2023 Dec 21 [cited 2026 Feb 1];71(3):245–52. Available from: https://www.jstage.jst.go.jp/article/endocrj/71/3/71_EJ23-0103/_html/-char/en
  65. Huang Y, Wang C, Cui H, Sun G, Qi X, Yao X. Mitochondrial dysfunction in age-related sarcopenia: mechanistic insights, diagnostic advances, and therapeutic prospects. Frontiers in Cell and Developmental Biology. 2025 Oct 3;13:1590524–4.
  66. Peng K, Pan Y, Li J, Khan Z, Fan M, Yin H, et al. 11β-Hydroxysteroid Dehydrogenase Type 1(11β-HSD1) mediates insulin resistance through JNK activation in adipocytes. Scientific Reports [Internet]. 2016 Nov 14;6(1):37160. Available from: https://www.nature.com/articles/srep37160
  67. Hamooya BM, Siame L, Muchaili L, Masenga SK, Kirabo A. Metabolic syndrome: epidemiology, mechanisms, and current therapeutic approaches. Frontiers in Nutrition. 2025 Sep 3;12.
  68. Bertollo AG, Santos CF, Bagatini MD, Ignácio ZM. Hypothalamus-pituitary-adrenal and gut-brain axes in biological interaction pathway of the depression. Frontiers in Neuroscience. 2025 Feb 6;19.
  69. Littlewood K, Jasleen Gegic, Hickman M, Henson RCJ, Bishop JR, Kershaw T, et al. Metabolic dysfunction over a life course key to healthy ageing inequality. Aging Clinical and Experimental Research. 2025 Jun 23;37(1).
  70. Siddiqui R, Rizwan Qaisar, Maciver S, Khan NA. Gut microbiome, stress and interventional strategies using hardy animals. Future Science OA. 2025 Nov 11;11(1):2583020–0.
  71. De Palma G, Collins SM, Bercik P. The microbiota-gut-brain axis in functional gastrointestinal disorders. Gut Microbes. 2014 May;5(3):419–29.
  72. Bear T, Dalziel J, Coad J, Roy N, Butts C, Gopal P. The Microbiome-Gut-Brain Axis and Resilience to Developing Anxiety or Depression under Stress. Microorganisms [Internet]. 2021 Apr 1;9(4):723. Available from: https://www.mdpi.com/2076-2607/9/4/723/htm
  73. Ring M. An Integrative Approach to HPA Axis Dysfunction: From Recognition to Recovery. The American Journal of Medicine. 2025 Jun;
  74. Nunn AV, Bell JD, Guy GW. Lifestyle-induced metabolic inflexibility and accelerated ageing syndrome: insulin resistance, friend or foe? Nutrition & Metabolism. 2009;6(1):16.
  75. Bautista J, Hidalgo-Tinoco C, Di M, Viteri-Recalde J, Guerra-Guerrero A, Andrés López-Cortés. The gut–brain–circadian axis in anxiety and depression: a critical review. Frontiers in Psychiatry. 2025 Oct 30;16.
  76. Pan D, Li J, Chen S, Gu S, Jiang M, Xu Q. Microbiota-gut-brain axis pathogenesis and targeted therapeutics in sleep disorders. Frontiers in Neurology [Internet]. 2025 Dec 12 [cited 2026 Feb 1];16:1721606–6. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC12740866/
  77. Zhao B, Sun J, Xiang L. Exercise as a modulator of gut microbiota for improvement of sleep quality: a narrative review. Frontiers in Neuroscience [Internet]. 2025 Nov 17;19:1639099–9. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC12665681/
  78. Li H, Gao J, Peng W, Sun X, Qi W, Wang Y. Dietary Polyphenols-Gut Microbiota Interactions: Intervention Strategies and Metabolic Regulation for Intestinal Diseases. Biology [Internet]. 2025 Nov 30 [cited 2026 Jan 10];14(12):1705–5. Available from: https://www.mdpi.com/2079-7737/14/12/1705
  79. Rias YA, Renny Wulan Apriliyasari, Made, Hasan F, Teli M, Chiu HY, et al. Effects of Physical and Mind-body Exercise on Sleep Quality in Individuals With Diabetes Mellitus: A Systematic Review and Meta?analysis. Journal of Preventive Medicine and Public Health [Internet]. 2024 Oct 7; Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC11824629/
  80. Hermanowski-Vosatka A, Balkovec JM, Cheng K, Chen HH, Hernandez M, Koo GC, et al. 11β-HSD1 inhibition ameliorates metabolic syndrome and prevents progression of atherosclerosis in mice. 2005 Aug 15;202(4):517–27.
  81. Szopa M, Małgorzata Wamil. 11beta-hydroxysteroid dehydrogenase type 1 inhibitor: a novel therapeutic target in the metabolic syndrome. Clinical Diabetology [Internet]. 2023 [cited 2026 Feb 1];8(3):77–83. Available from: https://journals.viamedica.pl/clinical_diabetology/article/view/8503/0
  82. Krishna Rao R. Role of Glutamine in Protection of Intestinal Epithelial Tight Junctions. Journal of Epithelial Biology and Pharmacology [Internet]. 2012 Jan 16;5(1):47–54. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4369670/
  83. Wang Y, Xiao J, Wei S, Su Y, Yang X, Su S, et al. Protective effect of zinc gluconate on intestinal mucosal barrier injury in antibiotics and LPS-induced mice. Frontiers in microbiology. 2024 May 23;15.
  84. Chudzik A, Orzyłowska A, Rola R, Stanisz GJ. Probiotics, Prebiotics and Postbiotics on Mitigation of Depression Symptoms: Modulation of the Brain–Gut–Microbiome Axis. Biomolecules. 2021 Jul 7;11(7):1000.
  85. gov. 2026. Available from: https://clinicaltrials.gov/study/NCT03111810
  86. Ji J, Jin W, Liu S, Zhang J, Li X. Probiotics, prebiotics, and postbiotics in health and disease. MedComm. 2023 Nov 4;4(6).
  87. Ansari F, M Neshat, Hadi Pourjafar, Seid Mahdi Jafari, Shohreh Alian Samakkhah, Esmaeel Mirzakhani. The role of probiotics and prebiotics in modulating of the gut-brain axis. Frontiers in Nutrition. 2023 Jul 26;10.
  88. Shapiro H, Suez J, Elinav E. Personalized microbiome-based approaches to metabolic syndrome management and prevention. Journal of Diabetes. 2017 Feb 2;9(3):226–36.
  89. Wu H, Lv B, Zhi L, Shao Y, Liu X, Mitteregger M, et al. Microbiome–metabolome dynamics associated with impaired glucose control and responses to lifestyle changes. Nature Medicine [Internet]. 2025 Apr 8; Available from: https://www.nature.com/articles/s41591-025-03642-6
  90. Abdul Manan M. The role of probiotics in personalized therapeutics: Advances in gut microbe-driven interventions. The Microbe [Internet]. 2025 Aug 6;8:100497. Available from: https://www.sciencedirect.com/science/article/pii/S2950194625002651
  91. Lonardo A, Byrne CD, Targher G. Precision medicine approaches in metabolic disorders and target organ damage: where are we now, and where are we going? Metabolism and Target Organ Damage. 2021;

Discover more from A1C Almanac

Subscribe now to keep reading and get access to the full archive.

Continue reading